Delivery Order SPE2DB22D2206-SPE2DB25FFV69

Award Date 2/26/25
Potential Completion Date 2/27/25
Potential Value $5.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,125.04 firm-fixed-price delivery order contract is for the supply of 4560879902 - CEFEPIME-DEXTROSE 2 GM/50 MLS, a pharmaceutical product. The contract has an ultimate completion date of May 10, 2023. AmerisourceBergen holds a substantial $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,359.28 firm-fixed-price delivery order is for the supply of CEFEPIME-DEXTROSE 2 GM/50 MLS medical products, with a period of performance through November 16, 2023. The contract has no set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $18,129.14 firm fixed-price delivery order is for the supply of 4565165651 CEFEPIME-DEXTROSE 2 GM/50 MLS, a pharmaceutical product. The contract has an ultimate completion date of July 17, 2024. This award is associated with AmerisourceBergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award, valued at $3,616.99, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the medical product "CEFEPIME-DEXTROSE 2 GM/50 MLS" and has an ultimate completion date of November 8, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $20,640.96 Firm Fixed Price Delivery Order covers the supply of the pharmaceutical product CEFEPIME-DEXTROSE 2 GM/50 MLS. This contract is not designated as a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,703.59 firm fixed-price delivery order contract, which has no set-aside designation, is for the provision of CEFEPIME-DEXTROSE 2 GM/50 MLS medical supplies. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for supplying...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,819.12 firm fixed-price delivery order is for the supply of CEFEPIME-DEXTROSE 2 GM/50 MLS, a pharmaceutical product. The contract has a completion date of June 21, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award, valued at $1,038.52, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4566449785 CEFEPIME-DEXTROSE 2 GM/50 MLS, a medical product, with a completion date of November 18, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type, and it is not designated with a Set-Aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,838.35, is for the supply of 4563433748 CEFEPIME-DEXTROSE 2 GM/50 MLS medical products. This is an open competition contract, with no set-aside designation. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This is a $16,913.70 Firm Fixed Price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the procurement of CEFEPIME-DEXTROSE 2 GM/50 MLS, a pharmaceutical product, with a performance period through June 4, 2024. This delivery order is placed under AmerisourceBergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB25FFV69
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,384.69 Firm Fixed Price Delivery Order is for the supply of 4567393733 ! CEFEPIME-DEXTROSE 2 GM/50 MLS, a medical product, with a performance period through February 27, 2025.

Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This specific Delivery Order is issued against that larger IDC contract. The contract award does not have a set-aside designation, indicating open competition.

Generated 5/28/25, 10:55 AM